Lightnews — Scholar-powered news

@cherryblossom60.bsky.social

230 followers 540 following 67 posts

I voted for HER both times

Posts Replies Media Videos

Reposted

Emma Mitchell

@silverpebble2.bsky.social

It would be so helpful if you could RT my post above about my Etsy shop. I haven't been able to work for more than half the year due to severe depression/a breakdown. If you see this & could spare a few moments for a RT it would help me put my designs in front of a few more eyes. Thankyou so much🌿

My blackbird necklace design. I hand-sculpt each of my bird necklaces individually in recycled silver.

November 23, 2025 at 12:07 PM

Reposted

Chise

@sailorrooscout.bsky.social

The study has been published in Alzheimer’s Research and Therapy. YES, it is PEER-REVIEWED.
• alzres.biomedcentral.com/articles/10....

🧪🧵⬇️

Abstract
Background
Alzheimer's disease (AD) is an escalating global challenge, with more than 40 million people affected, and this number is projected to increase to more than 100 million by 2050. While amyloid-targeting antibody treatments (lecanemab and donanemab) are a significant step forward, the benefits of these therapies remain limited. This highlights the necessity for safe and effective compounds that offer greater therapeutic benefits to the majority of individuals with or at risk of AD. Drug repurposing allows for a cost-effective, time-efficient strategy to accelerate the availability of treatments, owing to the availability of safety information.
Method
This study focuses on the third iteration of the Delphi consensus programme aimed at identifying new high-priority drug candidates for repurposing in AD. An international expert panel comprising academics, clinicians and industry representatives was convened.
Through a combination of anonymized drug nominations, systemic evidence reviews, iterative consensus rankings, and lay advisory inputs, drug candidates were evaluated and ranked based on rational, non-clinical, and clinical evidence and overall safety profiles.

Results
Among the 80 candidates that were nominated by the expert panel, seven underwent review, with only three candidates meeting the following consensus criteria of relevant mechanisms for targeting neurodegenerative pathways, non-clinical efficacy, and tolerability in older individuals. The three agents were: [1] the live attenuated herpes zoster (HZ) vaccine (Zostavax) [2], sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, and
[3] riluzole, a glutamate antagonist. The HZ vaccine additionally offers potential for population-level dementia risk reduction.
Conclusion
This Delphi consensus identified three high-priority drug repurposing candidates for AD with favourable safety profiles and mechanistic plausibility, which are considered suitable for pragmatic clinical trials, including remote or hybrid designs. The PROTECT platform, which supports international cohorts in the UK, Norway, and Canada, offers a well-established means to conduct such trials effectively, thus helping to accelerate the evaluation and potential deployment of these drug candidates to benefit individuals with or at risk for AD.

Triage of candidate treatments through the Delphi process

November 20, 2025 at 5:03 PM

Reposted

Elizabeth Jacobs, PhD

@elizabethjacobs.bsky.social

This is a fucking DISGRACE. The Republicans of the United States Congress are permitting a man to spew dangerous and harmful disinformation to the public.

This is dangerous. This will kill infants and children.

Republicans DO NOT CARE about babies after they are born

www.cdc.gov/vaccine-safe...

Autism and Vaccines

Answers to common questions about vaccine safety and autism.

www.cdc.gov

November 20, 2025 at 2:59 AM